scholarly journals Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier

2014 ◽  
Vol 15 (12) ◽  
Author(s):  
Filipe C Martins ◽  
Ines de Santiago ◽  
Anne Trinh ◽  
Jian Xian ◽  
Anne Guo ◽  
...  
2020 ◽  
Vol 159 ◽  
pp. 158
Author(s):  
O.T. Filippova ◽  
P. Selenica ◽  
S.S. Lee ◽  
X. Pei ◽  
N. Riaz ◽  
...  

2018 ◽  
Vol 17 ◽  
pp. 117693511875534 ◽  
Author(s):  
Yanina Natanzon ◽  
Madalene Earp ◽  
Julie M Cunningham ◽  
Kimberly R Kalli ◽  
Chen Wang ◽  
...  

High-grade serous ovarian cancer (HGSOC) is a complex disease in which initiation and progression have been associated with copy number alterations, epigenetic processes, and, to a lesser extent, germline variation. We hypothesized that, when summarized at the gene level, tumor methylation and germline genetic variation, alone or in combination, influence tumor gene expression in HGSOC. We used Elastic Net (ENET) penalized regression method to evaluate these associations and adjust for somatic copy number in 3 independent data sets comprising tumors from more than 470 patients. Penalized regression models of germline variation, with or without methylation, did not reveal a role in HGSOC gene expression. However, we observed significant association between regional methylation and expression of 5 genes ( WDPCP, KRT6C, BRCA2, EFCAB13, and ZNF283). CpGs retained in ENET model for BRCA2 and ZNF283 appeared enriched in several regulatory elements, suggesting that regularized regression may provide a novel utility for integrative genomic analysis.


Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1206 ◽  
Author(s):  
Sara Bouberhan ◽  
Lauren Philp ◽  
Sarah Hill ◽  
Linah F. Al-Alem ◽  
Bo Rueda

High-grade serous ovarian cancer (HGSOC) remains the most lethal gynecologic cancer in the United States. Genomic analysis revealed roughly half of HGSOC display homologous repair deficiencies. An improved understanding of the genomic and somatic mutations that influence DNA repair led to the development of poly(ADP-ribose) polymerase inhibitors for the treatment of ovarian cancer. In this review, we explore the preclinical and clinical studies that led to the development of FDA approved drugs that take advantage of the synthetic lethality concept, the implementation of the early phase trials, the development of companion diagnostics and proposed mechanisms of resistance.


2019 ◽  
Vol 6 ◽  
pp. 156-162 ◽  
Author(s):  
Surrin S. Deen ◽  
Frank Riemer ◽  
Mary A. McLean ◽  
Andrew B. Gill ◽  
Joshua D. Kaggie ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document